Ignite Creation Date:
2025-12-24 @ 3:28 PM
Ignite Modification Date:
2026-02-20 @ 5:56 PM
Study NCT ID:
NCT04929392
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-04
First Post:
2021-06-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer
Sponsor:
City of Hope Medical Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-01-25
Start Date Type:
ACTUAL
Primary Completion Date:
2027-04-25
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-04-25
Completion Date Type:
ESTIMATED
First Submit Date:
2021-06-11
First Submit QC Date:
None
Study First Post Date:
2021-06-18
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-27
Last Update Post Date:
2025-09-04
Last Update Post Date Type:
ESTIMATED